This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Enovis Corporation Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 03:45 PM
Canaccord Genuity Ups Price Target on Enovis to $75 From $73, Maintains Buy Rating MT
Needham Raises Price Target on Enovis to $82 From $73, Maintains Buy Rating MT
Enovis Seeks M&A CI
Transcript : Enovis Corporation, Q4 2023 Earnings Call, Feb 22, 2024
Nvidia Pushes Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday MT
Enovis Q4 Adjusted Earnings, Net Sales Increase MT
Earnings Flash (ENOV) ENOVIS CORPORATION Reports Q4 Revenue $455M, vs. Street Est of $445.4M MT
Enovis Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Enovis Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Enovis Corporation Provides Earnings Guidance for the Year 2024 CI
Stephens Initiates Enovis With Overweight Rating, $72 Price Target MT
Transcript : Enovis Corporation Presents at Canaccord Genuity's 2024 Musculoskeletal Conference, Feb-12-2024 02:30 PM
Enovis Corporation Showcases New Foot & Ankle Offerings at ACFAS Annual Meeting CI
Enovis Introduces the DonJoy ROAM? OA Knee Brace CI
UBS Initiates Coverage on Enovis With Buy Rating, $75 Price Target MT
Transcript : Enovis Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
William Blair Initiates Enovis at Outperform Rating MT
Enovis Completes LimaCorporate Acquisition MT
Enovis Corporation acquired Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT Partners AB and EQT VII for approximately ?450 million. CI
Canaccord Genuity Adjusts Enovis Price Target to $71 From $65, Maintains Buy Rating MT
Needham Adjusts Price Target on Enovis to $70 From $62, Keeps Buy Rating MT
Enovis President, Chief Operating Officer Brady Shirley to Resign MT
Enovis Corporation Announces Leadership Transition Plan CI
Transcript : Enovis Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:00 AM
Chart Enovis Corporation
More charts
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
56.81 USD
Average target price
75.2 USD
Spread / Average Target
+32.37%
Consensus
  1. Stock Market
  2. Equities
  3. ENOV Stock
  4. News Enovis Corporation
  5. Insider Trends: Colfax Sees 90 Days of Insider Buying Trend Scaling Back with Share Sale